Manoela K Riekes1,2, Axel Engelen1, Bernard Appeltans1, Patrick Rombaut1, Hellen K Stulzer2, Guy Van den Mooter3. 1. Department of Pharmaceutical and Pharmacological Sciences, Drug Delivery and Disposition, KU Leuven, Campus Gasthuisberg ON2, Herestraat 49 b921, 3000, Leuven, Belgium. 2. Laboratório de Controle de Qualidade, Departamento de Ciências Farmacêuticas, Universidade Federal de Santa Catarina, Campus Reitor João David Ferreira Lima, Trindade, 88040-970, Florianópolis, SC, Brazil. 3. Department of Pharmaceutical and Pharmacological Sciences, Drug Delivery and Disposition, KU Leuven, Campus Gasthuisberg ON2, Herestraat 49 b921, 3000, Leuven, Belgium. guy.vandenmooter@pharm.kuleuven.be.
Abstract
PURPOSE: Aiming to improve the dissolution rate of ezetimibe (EZE) and lovastatin (LOV) in a fixed dose combination (FDC), co-amorphous systems and ternary solid dispersions were prepared by quench cooling and spray drying, respectively. METHODS: Formulations were characterized through X-ray diffraction, modulated differential scanning calorimetry, infrared spectroscopy, scanning electron microscopy and laser diffraction, and evaluated by 'in vitro' dissolution. Stability studies were conducted at different conditions during 30 days with the ternary solid dispersion composed of 75% of Soluplus® (ELS 1:1 75%). RESULTS: Single phase co-amorphous systems made up of the pure drugs were not able to increase the dissolution rate of EZE and LOV. However, ternary solid dispersions achieved high dissolution for both compounds, especially when Soluplus® was used as carrier. The dissolution efficiency increased up to 18 (EZE) and 6 (LOV) times in ternary solid dispersions, compared to the crystalline drugs. ELS 1:1 75% preserved its amorphous state during 30 days, in different stability conditions. CONCLUSIONS: A spray dried ternary solid dispersion able to enhance the dissolution rate of two poorly soluble, therapeutically complementary drugs, is reported for the first time. These promising results open new perspectives for the development of more advanced FDCs.
PURPOSE: Aiming to improve the dissolution rate of ezetimibe (EZE) and lovastatin (LOV) in a fixed dose combination (FDC), co-amorphous systems and ternary solid dispersions were prepared by quench cooling and spray drying, respectively. METHODS: Formulations were characterized through X-ray diffraction, modulated differential scanning calorimetry, infrared spectroscopy, scanning electron microscopy and laser diffraction, and evaluated by 'in vitro' dissolution. Stability studies were conducted at different conditions during 30 days with the ternary solid dispersion composed of 75% of Soluplus® (ELS 1:1 75%). RESULTS: Single phase co-amorphous systems made up of the pure drugs were not able to increase the dissolution rate of EZE and LOV. However, ternary solid dispersions achieved high dissolution for both compounds, especially when Soluplus® was used as carrier. The dissolution efficiency increased up to 18 (EZE) and 6 (LOV) times in ternary solid dispersions, compared to the crystalline drugs. ELS 1:1 75% preserved its amorphous state during 30 days, in different stability conditions. CONCLUSIONS: A spray dried ternary solid dispersion able to enhance the dissolution rate of two poorly soluble, therapeutically complementary drugs, is reported for the first time. These promising results open new perspectives for the development of more advanced FDCs.
Authors: Luz María Martínez; Marcelo Videa; Gladys A López-Silva; Carlos A de Los Reyes; Jorge Cruz-Angeles; Nahida González Journal: Int J Pharm Date: 2014-10-19 Impact factor: 5.875
Authors: Boris Kerzner; John Corbelli; Stephan Sharp; Leslie J Lipka; Lorenzo Melani; Alexandre LeBeaut; Ramachandran Suresh; Pabak Mukhopadhyay; Enrico P Veltri Journal: Am J Cardiol Date: 2003-02-15 Impact factor: 2.778
Authors: Morten Allesø; Norman Chieng; Sönke Rehder; Jukka Rantanen; Thomas Rades; Jaakko Aaltonen Journal: J Control Release Date: 2009-02-10 Impact factor: 9.776